Publication: Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy (review)
dc.contributor.author | Kiyoshi Kikuchi | en_US |
dc.contributor.author | Ko Ichi Kawahara | en_US |
dc.contributor.author | Naoki Miura | en_US |
dc.contributor.author | Takashi Ito | en_US |
dc.contributor.author | Yoko Morimoto | en_US |
dc.contributor.author | Salunya Tancharoen | en_US |
dc.contributor.author | Nobuyuki Takeshige | en_US |
dc.contributor.author | Hisaaki Uchikado | en_US |
dc.contributor.author | Rokudai Sakamoto | en_US |
dc.contributor.author | Naohisa Miyagi | en_US |
dc.contributor.author | Chiemi Kikuchi | en_US |
dc.contributor.author | Narumi Iida | en_US |
dc.contributor.author | Naoto Shiomi | en_US |
dc.contributor.author | Terukazu Kuramoto | en_US |
dc.contributor.author | Masaru Hirohata | en_US |
dc.contributor.author | Ikuro Maruyama | en_US |
dc.contributor.author | Motohiro Morioka | en_US |
dc.contributor.author | Eiichiro Tanaka | en_US |
dc.contributor.other | Yame Public Hospital | en_US |
dc.contributor.other | Kurume University School of Medicine | en_US |
dc.contributor.other | Osaka Institute of Technology | en_US |
dc.contributor.other | Kagoshima University Faculty of Medicine | en_US |
dc.contributor.other | Kagoshima University | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Nishida Koutoku Hospital | en_US |
dc.contributor.other | Kohjin Co., Ltd. | en_US |
dc.contributor.other | Saiseikai Shiga Hospital | en_US |
dc.contributor.other | Omuta City General Hospital | en_US |
dc.date.accessioned | 2018-06-11T04:35:53Z | |
dc.date.available | 2018-06-11T04:35:53Z | |
dc.date.issued | 2012-07-01 | en_US |
dc.description.abstract | Stroke is a major cause of mortality and disability worldwide. During the past three decades, major advances have occurred in secondary prevention, which have demonstrated the broader potential for the prevention of stroke. Risk factors for stroke include previous stroke or transient ischemic attack, hypertension, high blood cholesterol and diabetes. Proven secondary prevention strategies are antiplatelet agents, antihypertensive drugs, statins and glycemic control. In the present review, we evaluated the secondary prevention of stroke in light of clinical studies and discuss new pleiotropic effects beyond the original effects and emerging clinical evidence, with a focus on the effect of optimal oral pharmacotherapy. | en_US |
dc.identifier.citation | Experimental and Therapeutic Medicine. Vol.4, No.1 (2012), 3-7 | en_US |
dc.identifier.doi | 10.3892/etm.2012.560 | en_US |
dc.identifier.issn | 17921015 | en_US |
dc.identifier.issn | 17920981 | en_US |
dc.identifier.other | 2-s2.0-84865708761 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/13689 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84865708761&origin=inward | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.subject | Immunology and Microbiology | en_US |
dc.title | Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy (review) | en_US |
dc.type | Review | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84865708761&origin=inward | en_US |